Tokio Marine Asset Management Co. Ltd. Sells 2,739 Shares of Eli Lilly and Company $LLY

Tokio Marine Asset Management Co. Ltd. cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.5% during the 3rd quarter, Holdings Channel.com reports. The fund owned 47,193 shares of the company’s stock after selling 2,739 shares during the period. Eli Lilly and Company accounts for about 1.3% of Tokio Marine Asset Management Co. Ltd.’s portfolio, making the stock its 14th biggest position. Tokio Marine Asset Management Co. Ltd.’s holdings in Eli Lilly and Company were worth $36,008,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. Brighton Jones LLC increased its position in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after acquiring an additional 40 shares during the period. Salem Investment Counselors Inc. increased its holdings in Eli Lilly and Company by 0.6% in the 2nd quarter. Salem Investment Counselors Inc. now owns 71,869 shares of the company’s stock worth $56,024,000 after acquiring an additional 426 shares during the last quarter. Wealth Alliance Advisory Group LLC raised its stake in Eli Lilly and Company by 4.5% in the 2nd quarter. Wealth Alliance Advisory Group LLC now owns 4,861 shares of the company’s stock valued at $3,789,000 after acquiring an additional 211 shares during the period. Finally, New Capital Management LP purchased a new stake in Eli Lilly and Company during the second quarter valued at about $223,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 1.6%

Shares of NYSE LLY opened at $1,080.92 on Tuesday. The stock has a market capitalization of $1.02 trillion, a P/E ratio of 52.88, a PEG ratio of 0.77 and a beta of 0.35. The firm’s 50 day simple moving average is $1,040.85 and its two-hundred day simple moving average is $863.67. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same period in the prior year, the business posted $1.18 earnings per share. The company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Nvidia co‑innovation AI lab — Nvidia and Lilly will commit up to $1 billion over five years to a San Francisco‑area AI drug discovery lab that will run Nvidia’s newest Vera Rubin AI chips; the partnership could speed candidate discovery, improve R&D productivity and lower time‑to‑market for future programs. Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab
• Positive Sentiment: Management says orforglipron supply is ready — Lilly told investors it’s confident in pill supply ahead of expected U.S. approval, reducing a near‑term execution risk that would otherwise pressure launches and early sales. Lilly says it’s confident weight-loss pill supply ahead of U.S. approval
• Positive Sentiment: Ventyx acquisition adds inflammation program that could complement GLP‑1 franchise — Investors cheered Lilly’s deal for Ventyx (adds VTX3232 data showing inflammation benefit with GLP‑1), which could become an add‑on therapy and extend addressable market for Lilly’s weight‑loss/diabetes drugs.
• Neutral Sentiment: Aktis Oncology stake and biotech deal exposure — Lilly anchored Aktis’ IPO and holds a meaningful equity/stake that gives exposure to targeted radiopharma programs; strategic but long‑dated and dependent on clinical milestones. Aktis Oncology aims to raise up to $317.7 million in IPO
• Neutral Sentiment: Analyst/coverage pieces highlight growth case and new tech investments — Multiple outlets and analysts are reiterating Lilly’s growth story (tirzepatide momentum, pipeline upside) and noting Lilly is building advanced compute/supercomputer capacity; that supports a bullish narrative but is forward‑looking. Here’s Why Eli Lilly (LLY) is a Strong Growth Stock
• Negative Sentiment: Competition from Novo Nordisk’s Wegovy Pill — Novo’s U.S. roll‑out of an oral Wegovy competitor raises market‑share risk for Lilly’s upcoming orforglipron launch and is a clear near‑term competitive headwind priced by investors. Novo Nordisk launches Wegovy Pill in the U.S.

Analysts Set New Price Targets

Several analysts have recently issued reports on LLY shares. JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Daiwa Capital Markets set a $1,230.00 price objective on Eli Lilly and Company and gave the company a “buy” rating in a research note on Tuesday, December 16th. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. Scotiabank started coverage on Eli Lilly and Company in a report on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 target price for the company. Finally, Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Five equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $1,169.00.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.